Latest United Therapeutics Corp (UTHR) Headlines
Look for Shares of United Therapeutics to Potentially Rebound after Yesterday's 4.97% Sell Off
Comtex SmarTrend(R) - Tue Mar 11, 5:53PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.00 to a high of $100.10. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $97.42 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 4.97%
Comtex SmarTrend(R) - Tue Mar 11, 5:53PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.00 to a high of $100.10. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $97.42 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics Earnings Hindsight: Up 0.5% in Last 13 Days (UTHR)
Comtex SmarTrend(R) - Mon Mar 10, 7:49AM CDT
When United Therapeutics (NASDAQ:UTHR) reported earnings 13 days ago on February 25th, 2014, analysts, on average, expected the company to report earnings of $2.62 on sales of $297.8 million. The company actually reported EPS of $2.88 on sales of $289.0 million, beating EPS estimates by $0.26 and missing revenue estimates by $8.8 million. Shares of United Therapeutics have climbed from $100.50 to $100.96, representing a gain of 0.5% since the company reported earnings 13 days ago.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Stock Movements, Upcoming Conferences, Financial Results, and Public Offering Closings - Analyst Notes on Community Health Systems, United Therapeutics, Thoratec, AMRI, and Cytokinetics
PR Newswire - Wed Mar 05, 6:15AM CST
Editor Note: For more information about this release, please scroll to bottom.
InterMune Stuns Markets, but Is It Overvalued?
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 28, 5:03PM CST
InterMune told investors during its fourth quarter conference call that results from its phase 3 Ascend trial studying Esbriet in idiopathic pulmonary fibrosis, or IPF, would likely be released early in the second quarter. Investors ended up...
United Therapeutics Slips on Q4 Earnings Report - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:10AM CST
The company's revenues lagged expectations.
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
United Therapeutics Falls 3.86% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Feb 25, 6:08PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $99.16 to a high of $106.89. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $101.71 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of United Therapeutics After 3.86% Loss
Comtex SmarTrend(R) - Tue Feb 25, 6:07PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $99.16 to a high of $106.89. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $101.71 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics Q4 Revenue Misses, Stock Slides
at Investor's Business Daily - Tue Feb 25, 11:17AM CST
Biotech United Therapeutics (UTHR) missed Q4 sales estimates and reported higher-than-expected expenses Tuesday, sending shares down 1% in midday trading on the stock market today. The company said sales totaled $289 million, up 19% from the...
United Therapeutics Corporation Reports 2013 Fourth Quarter And Annual Financial Results
PR Newswire - Tue Feb 25, 5:00AM CST
-- Total Annual Revenues of $1.1 billion
Pipeline Progress at Pluristem - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 4:50PM CST
Pluristem recently announced that it has submitted its application to the U.S. Food and Drug Administration (FDA) to grant orphan drug designation to its PLX-PAD cells for the treatment of severe preeclampsia.
Cempra (CEMP) Jumps: Stock Adds 6.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 8:39AM CST
Cempra, Inc. was a big mover last session, as its shares rose just over 6% on the day.
The Zacks Analyst Blog Highlights: Sanofi, Regeneron Pharmaceuticals, United Therapeutics, Medivation and Idenix Pharmaceuticals
PR Newswire - Fri Feb 21, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sanofi (NYSE:SNY-Free Report), Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN-Free Report), United Therapeutics Corporation (Nasdaq:UTHR-Free Report), Medivation, Inc. (Nasdaq:MDVN-Free Report) and Idenix Pharmaceuticals Inc. (Nasdaq:IDIX-Free Report).
3 Biotech Stocks to Bet on this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:39AM CST
It is not too late to join the biotech bandwagon.
United Therapeutics Corporation To Announce Fourth Quarter And Annual 2013 Financial Results Before Market Open On Tuesday, February 25, 2014
PR Newswire - Tue Feb 18, 5:00AM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its fourth quarter and annual 2013 financial results before market open on Tuesday, February 25, 2014.
Pluristem Receives Key 3D Cell Expansion Patent in Australia
GlobeNewswire - Tue Feb 18, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASELTR), a leading developer of placenta-based cell therapies, today announced it has been granted a new patent by the Australian Patent Office. Patent #2007228341 covers the method and composition of matter for three-dimensional (3D) expansion of placental or adipose (fat) stromal cells, Pluristem's key technology platform. Patent claims also include methods of treatment using placental cells for numerous diseases including graft vs. host disease (GvHD), heart disease, stroke, burns, loss of tissue, loss of blood, anemia, and autoimmune disorders. Patents with similar claims have also been granted to Pluristem in Russia and in South Africa. This marks Pluristem's third patent issued in Australia and its 28th patent issued worldwide.
The Zacks Analyst Blog Highlights: CNA Financial, Loews, FBL Financial Group, Pluristem Therapeutics and United Therapeutics
PR Newswire - Wed Feb 05, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the CNA Financial Corp. (NYSE:CNA-Free Report), Loews Corp. (NYSE:L-Free Report), FBL Financial Group Inc. (NYSE:FFG-Free Report), Pluristem Therapeutics, Inc. (NasdaqSTI-Free Report) and United Therapeutics (Nasdaq:UTHR-Free Report).
Study on Pluristem's Placental Cells - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 4:40PM CST
Pluristem Therapeutics, Inc. (PSTI) recently announced that the NIAID will initiate a mechanism-of-action study to evaluate Pluristem's PLacental eXpanded RAD (PLX-RAD) cells for the treatment of acute radiation syndrome (ARS).
Look for Shares of United Therapeutics to Potentially Rebound after Yesterday's 4.97% Sell Off
Comtex SmarTrend(R) - Tue Mar 11, 5:53PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.00 to a high of $100.10. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $97.42 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 4.97%
Comtex SmarTrend(R) - Tue Mar 11, 5:53PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.00 to a high of $100.10. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $97.42 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics Earnings Hindsight: Up 0.5% in Last 13 Days (UTHR)
Comtex SmarTrend(R) - Mon Mar 10, 7:49AM CDT
When United Therapeutics (NASDAQ:UTHR) reported earnings 13 days ago on February 25th, 2014, analysts, on average, expected the company to report earnings of $2.62 on sales of $297.8 million. The company actually reported EPS of $2.88 on sales of $289.0 million, beating EPS estimates by $0.26 and missing revenue estimates by $8.8 million. Shares of United Therapeutics have climbed from $100.50 to $100.96, representing a gain of 0.5% since the company reported earnings 13 days ago.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Stock Movements, Upcoming Conferences, Financial Results, and Public Offering Closings - Analyst Notes on Community Health Systems, United Therapeutics, Thoratec, AMRI, and Cytokinetics
PR Newswire - Wed Mar 05, 6:15AM CST
Editor Note: For more information about this release, please scroll to bottom.
InterMune Stuns Markets, but Is It Overvalued?
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 28, 5:03PM CST
InterMune told investors during its fourth quarter conference call that results from its phase 3 Ascend trial studying Esbriet in idiopathic pulmonary fibrosis, or IPF, would likely be released early in the second quarter. Investors ended up...
United Therapeutics Slips on Q4 Earnings Report - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:10AM CST
The company's revenues lagged expectations.
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
United Therapeutics Falls 3.86% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Feb 25, 6:08PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $99.16 to a high of $106.89. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $101.71 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of United Therapeutics After 3.86% Loss
Comtex SmarTrend(R) - Tue Feb 25, 6:07PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $99.16 to a high of $106.89. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $101.71 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics Q4 Revenue Misses, Stock Slides
at Investor's Business Daily - Tue Feb 25, 11:17AM CST
Biotech United Therapeutics (UTHR) missed Q4 sales estimates and reported higher-than-expected expenses Tuesday, sending shares down 1% in midday trading on the stock market today. The company said sales totaled $289 million, up 19% from the...
United Therapeutics Corporation Reports 2013 Fourth Quarter And Annual Financial Results
PR Newswire - Tue Feb 25, 5:00AM CST
-- Total Annual Revenues of $1.1 billion
Pipeline Progress at Pluristem - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 4:50PM CST
Pluristem recently announced that it has submitted its application to the U.S. Food and Drug Administration (FDA) to grant orphan drug designation to its PLX-PAD cells for the treatment of severe preeclampsia.
Cempra (CEMP) Jumps: Stock Adds 6.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 8:39AM CST
Cempra, Inc. was a big mover last session, as its shares rose just over 6% on the day.
The Zacks Analyst Blog Highlights: Sanofi, Regeneron Pharmaceuticals, United Therapeutics, Medivation and Idenix Pharmaceuticals
PR Newswire - Fri Feb 21, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sanofi (NYSE:SNY-Free Report), Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN-Free Report), United Therapeutics Corporation (Nasdaq:UTHR-Free Report), Medivation, Inc. (Nasdaq:MDVN-Free Report) and Idenix Pharmaceuticals Inc. (Nasdaq:IDIX-Free Report).
3 Biotech Stocks to Bet on this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:39AM CST
It is not too late to join the biotech bandwagon.
United Therapeutics Corporation To Announce Fourth Quarter And Annual 2013 Financial Results Before Market Open On Tuesday, February 25, 2014
PR Newswire - Tue Feb 18, 5:00AM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its fourth quarter and annual 2013 financial results before market open on Tuesday, February 25, 2014.
Pluristem Receives Key 3D Cell Expansion Patent in Australia
GlobeNewswire - Tue Feb 18, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASELTR), a leading developer of placenta-based cell therapies, today announced it has been granted a new patent by the Australian Patent Office. Patent #2007228341 covers the method and composition of matter for three-dimensional (3D) expansion of placental or adipose (fat) stromal cells, Pluristem's key technology platform. Patent claims also include methods of treatment using placental cells for numerous diseases including graft vs. host disease (GvHD), heart disease, stroke, burns, loss of tissue, loss of blood, anemia, and autoimmune disorders. Patents with similar claims have also been granted to Pluristem in Russia and in South Africa. This marks Pluristem's third patent issued in Australia and its 28th patent issued worldwide. The Zacks Analyst Blog Highlights: CNA Financial, Loews, FBL Financial Group, Pluristem Therapeutics and United Therapeutics
PR Newswire - Wed Feb 05, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the CNA Financial Corp. (NYSE:CNA-Free Report), Loews Corp. (NYSE:L-Free Report), FBL Financial Group Inc. (NYSE:FFG-Free Report), Pluristem Therapeutics, Inc. (Nasdaq
STI-Free Report) and United Therapeutics (Nasdaq:UTHR-Free Report). Study on Pluristem's Placental Cells - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 4:40PM CST
Pluristem Therapeutics, Inc. (PSTI) recently announced that the NIAID will initiate a mechanism-of-action study to evaluate Pluristem's PLacental eXpanded RAD (PLX-RAD) cells for the treatment of acute radiation syndrome (ARS).
